Navigation Links
Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Date:6/4/2008

SEATTLE, June 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Kendall Mohler, co-founder and senior vice president of research and development, is scheduled to present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference on June 12 at 10 a.m. EDT. This conference will be held at the New York Palace Hotel in New York City. The presentation will be available via audio webcast at http://www.wsw.com/webcast/needham25/trbn/ and will be available in the investors section of Trubion's website, investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candid
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Announces Presentations at April/May Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
3. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
7. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
8. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
9. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
10. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
11. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Minn. (PRWEB) March 06, 2015 ... Scientific Symposia sessions for the grain scientists’ Centennial ... abstracts. , 2015 marks the 100th anniversary ... Centennial Meeting in Minneapolis, Minnesota, U.S.A. on October ... from international researchers who are looking to the ...
(Date:3/6/2015)... , March 6, 2015   Senomyx , ... using proprietary taste science technologies to discover, develop, and ... flavor industries, announced today that John Poyhonen , the ... Rogers , Senior Vice President and Chief Financial Officer, ... currently scheduled for Wednesday, March 11, at 2:00 p.m. ...
(Date:3/6/2015)... PARIS , March 6, 2015 /PRNewswire/ ... im Dezember   2011 von der Assistance ... initiiert., Sie ist eine französische, ... 400   Patienten rekrutiert wurden. Verglichen werden ... entweder mit Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt ...
(Date:3/5/2015)... Buffalo, New York (PRWEB) March 05, 2015 ... want veterans to be able to get an Advanced ... Time, money, stress, blaming and guessing are all risk ... with assuming the woman is the source of the ... and female. LifeCell Dx has the simplest, least ...
Breaking Biology Technology:AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... interpretation, storage and documentation of photograph files focused on ... June 10 EyeIC, an innovator of eye care ... MatchedFlicker(TM) technology has received FDA 510(k) clearance from the ... is a device-agnostic, software-only solution that uses time series ...
... LAKE, N.J., June 10 Strativa Pharmaceuticals, the proprietary ... Pharmaceutical Companies, Inc. (NYSE: PRX ), today ... has accepted its New Drug Application (NDA) for ondansetron ... of ondansetron ODFS for the prevention of nausea and ...
... YORK, June 10 NeoStem, Inc. (NYSE Amex: ... long-term storage of adult stem cells for future medical need, ... Drew Bernstein, CPA and Managing Partner of Bernstein & Pinchuk ... Committee. , , Mr. Bernstein co-founded Bernstein & Pinchuk ...
Cached Biology Technology:EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology 2EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology 3Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 2Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA 3NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Company's Audit Committee 2NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Company's Audit Committee 3
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... Technology Professor Xiaojun Yu, Ph.D., has received an ... from the Wallace H. Coulter Foundation. This award ... scaffolds for bone healing. , Yu, Assistant Professor ... Engineering at Stevens Schaefer School of Engineering and ...
... The American Institute of Biological Sciences (AIBS), in conjunction ... fourth annual symposium on evolution on December 1, 2007, ... symposium, titled Evolution: Applications in Human Health and Populations, ... by the National Association of Biology Teachers. ...
... have brought us the resurgence of American bald ... prized lobster fisheries. So how can modern conservation ... catastrophic loss of Guatemalan forests to the economy-crippling ... this week,s special issue of the Proceedings of ...
Cached Biology News:AIBS to cohost symposium on evolution, disease and human health 2AIBS to cohost symposium on evolution, disease and human health 3AIBS to cohost symposium on evolution, disease and human health 4Why conservation efforts often fail 2
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Complete kit for all types of yeast two-hybrid ... Choice of two bait ... baits , Triple ... Complete set of ...
Biology Products: